Balance Sheet
Liabilities and Shareholders Equity
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Current Deferred Revenue (2018 - 2020)

KalVista Pharmaceuticals' Current Deferred Revenue history spans 5 years, with the latest figure at $1.3 million for Q1 2020.

  • For Q1 2020, Current Deferred Revenue fell 89.09% year-over-year to $1.3 million; the TTM value through Jan 2020 reached $1.3 million, down 89.09%, while the annual FY2019 figure was $9.5 million, 48.34% down from the prior year.
  • Current Deferred Revenue for Q1 2020 was $1.3 million at KalVista Pharmaceuticals, down from $2.6 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $20.0 million in Q1 2018 and bottomed at $1.3 million in Q1 2020.
  • The 3-year median for Current Deferred Revenue is $12.3 million (2019), against an average of $11.4 million.
  • The largest annual shift saw Current Deferred Revenue crashed 38.43% in 2019 before it crashed 89.09% in 2020.
  • A 3-year view of Current Deferred Revenue shows it stood at $14.8 million in 2018, then tumbled by 82.39% to $2.6 million in 2019, then crashed by 48.37% to $1.3 million in 2020.
  • Per Business Quant, the three most recent readings for KALV's Current Deferred Revenue are $1.3 million (Q1 2020), $2.6 million (Q4 2019), and $6.0 million (Q3 2019).